RxDoctor Payments DataLook up a doctor →

Victor Gian, MD

Medical Oncology · Murfreesboro, TNNPI 1205878402

Payments from drug & device makers

$47,559in general payments, 2019–2025

Across 347 payments — averaging $137.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$25K
  • Karyopharm Therapeutics Inc.$5K
  • Beigene USA, Inc.$3K
  • GSK$3K
  • Array Biopharma Inc$2K
  • AstraZeneca$2K
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$8,42318%
  • Speaking & faculty fees$31,91567%
  • Food & beverage$7,08615%
  • Education$1360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen29$25,428
Karyopharm Therapeutics Inc.4$5,284
Beigene USA, Inc.4$3,365
GSK6$3,027
Array Biopharma Inc7$1,986
AstraZeneca(2 entities)27$1,893
Johnson & Johnson15$1,094
Novartis27$563
Merck18$339
E.r. Squibb & Sons, L.L.C.18$324
Bristol Myers Squibb13$295
Astellas Pharma US Inc14$275
Regeneron Healthcare Solutions, Inc.9$255
Heron Therapeutics, Inc.2$194
Genentech USA, Inc.13$181
Incyte Corporation8$175
Daiichi Sankyo Inc.6$163
Sanofi7$159
Eisai Inc.7$155
AbbVie8$149
Bayer7$147
Eagle Pharmaceuticals, Inc.1$125
Ipsen Biopharmaceuticals, Inc5$116
Pfizer8$109
AVEO Pharmaceuticals, Inc.4$107
Gilead(2 entities)6$105
Mirati Therapeutics, Inc.2$103
Puma Biotechnology, Inc.5$97
Exelixis Inc.4$91
Takeda Pharmaceuticals U.S.A., Inc.4$91
Jazz Pharmaceuticals Inc.4$85
Tersera Therapeutics LLC4$84
Deciphera Pharmaceuticals Inc.3$75
Genmab U.S., Inc.3$73
Lilly USA, LLC4$72
Taiho Oncology, Inc.3$64
ADC Therapeutics America, Inc.3$60
Pharmaessentia USA Corporation2$52
Iovance Biotherapeutics, Inc.2$50
Agios Pharmaceuticals, Inc.2$43
Sun Pharmaceutical Industries Inc.2$38
Legend Biotech USA Inc.1$37
EMD Serono, Inc.2$37
Rigel Pharmaceuticals, Inc.2$36
Morphosys, US Inc.2$31
Teva Pharmaceuticals USA, Inc.2$28
Boehringer Ingelheim1$26
Blueprint Medicines Corporation1$25
Servier Pharmaceuticals LLC1$21
Dova Pharmaceuticals1$21
Biocompatibles, Inc.1$21
Geron Corporation1$20
Stemline Therapeutics Inc.1$17
Pharmacosmos Therapeutics Inc.1$17
Partner Therapeutics, Inc.1$17
Coherus Oncology, Inc.1$16
Clovis Oncology, Inc.2$16
CTI Biopharma Corp.1$15
Cycle Pharmaceuticals Inc1$15
Sumitomo Pharma America, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,559 in reported general payments places this provider in the 60th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,859,635
Medicare patients
603
Services billed
132,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide103$1,407,733
RevlimidLenalidomide52$887,458
ImbruvicaIbrutinib24$383,261
KisqaliRibociclib Succinate19$314,414
VerzenioAbemaciclib20$285,331
CalquenceAcalabrutinib Maleate17$256,059
JakafiRuxolitinib Phosphate17$239,031
BrukinsaZanubrutinib16$237,373
VenclextaVenetoclax20$162,566
NinlaroIxazomib Citrate11$126,216
EliquisApixaban109$85,853
PegasysPeginterferon Alfa-2a12$52,586
Abiraterone Acetate23$32,175
XareltoRivaroxaban33$28,903
Exemestane40$6,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$275$1,407,733103 claims
Bristol Myers SquibbRevlimid$295$887,45852 claims
NovartisKisqali$563$314,41419 claims
Lilly USA, LLCVerzenio$72$285,33120 claims
AstraZenecaCalquence$1,893$256,05917 claims
Incyte CorporationJakafi$175$239,03117 claims
Beigene USA, Inc.Brukinsa$3,365$237,37316 claims
AbbVieVenclexta$149$162,56620 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$91$126,21611 claims
PfizerEliquis$109$85,853109 claims
Johnson & JohnsonXarelto$1,094$28,90333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 101 medical oncology providers in Tennessee.

Other medical oncology in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →